Job Trends
Labor Market Reports
BioSpace’s 2026 U.S. Life Sciences Employment Outlook examines the state of the biopharma workforce amid ongoing funding pressure, elevated layoffs and cautious hiring sentiment, while highlighting early signals of stabilization and cautious optimism for the year ahead.
BioSpace’s 2025 Q4 U.S. Life Sciences Job Market update highlights early signs of stabilization in biopharma hiring, with modest gains in job postings, slowing layoffs, and cautiously improving sentiment heading into 2026.
BioSpace’s Q3 2025 U.S. Life Sciences Job Market Report reveals a turbulent quarter for biopharma hiring, with record declines in job postings, rising layoffs, and cautious employer sentiment shaping the industry’s employment landscape.
Now Hiring
Looking for an IT job? From data engineer to information security, check out the BioSpace list of 10 companies hiring life sciences professionals like you.
More biopharma organizations were actively recruiting at the end of 2025 than 2024, based on the new BioSpace employment outlook report. Areas in demand this year include research and development and clinical. Organizations are also prioritizing artificial intelligence hires.
Looking for a research and development job? Check out the BioSpace list of 12 companies hiring life sciences professionals like you.
Career Advice
With leaner teams and tighter budgets, senior leaders can face tremendous strain as they juggle increased workloads and leadership responsibilities. In this column, Kaye/Bassman’s Michael Pietrack discusses how pressure builds and what can ease it.
THE LATEST
The USPTO is paving the way for generic challengers to J&J’s prostate cancer drug Zytiga.
On Jan. 8, Alder BioPharma announced that its eptinezumab met its primary endpoint in its Phase III PROMISE 2 clinical trial for preventing migraine.
The rumors have caused Juno’s stock to rocket more than 50 percent to $68.80 in premarket trading.
Thirty years ago, neurologist Leonard S. Schliefer, MD, PhD, founded Regeneron, a life sciences company dedicated to discovering, developing and bringing new medications to the patients who need them.
The new space for biotechs is available following investments from Alexandria Real Estate Equities in this city.
Merck’s Keytruda has done it again.
Ra Medical only has five full-time salespeople on staff, but expects that to grow to 20 to 25 people later this year.
The news was disclosed by Ruyi He, MD, Chief Scientist of the CFDA and the Center for Drug Evaluation.
Changes are coming to Medtronic.
Here is a look at key takeaways from presentations made by four major pharma and biotech stocks at the annual J.P. Morgan healthcare conference.